Cover; Preface to Sequence-specific DNA Binding Agents; Preface; Contents; Chapter 1 DNA Recognition by Parallel Triplex Formation; 1.1 Why Triplexes?; 1.1.1 Triplets and Triplex Motifs; 1.1.2 Base, Sugar and/or Phosphate Modifications; 1.2 Stabilising Triplexes; 1.2.1 Enhancing Stacking and Hydrophobic Interactions; 1.2.2 Locking the Sugar Pucker; 1.2.3 Adding Positive Charge(s); 1.2.4 Removing Negative Charge(s); 1.2.5 Triplex-binding and Cross-linking Agents; 1.3 Decreasing pH Dependence; 1.3.1 Pyrimidine Analogues; 1.3.2 Purine Analogues; 1.4 Recognising Pyrimidine-Purine Base Pairs
Text of Note
1.4.1 Null Bases and Abasic Linkers1.4.2 Natural Bases; 1.4.3 Analogues for CG Recognition; 1.4.4 Analogues for TA Recognition; 1.4.5 Other Approaches; 1.5 Towards Mixed Sequence Recognition at Neutral pH; 1.6 Outlook; Acknowledgements; References; Chapter 2 Interfacial Inhibitors; 2.1 Introduction; 2.2 Case Studies; 2.2.1 Topoisomerase Inhibitors; 2.2.2 HIV Integrase Strand Transfer Inhibitors; 2.2.3 STING Inhibitors; 2.2.4 Arp2-3 Inhibitors; 2.3 Prospects; Acknowledgements; References; Chapter 3 Slow DNA Binding; 3.1 Introduction-Kinetics vs. Thermodynamics of DNA Binding
Text of Note
4.2.1 Analysis of Tm shifts in the Presence of Drug4.2.2 Obtaining Binding Enthalpy Values by DSC; 4.2.3 Modeling Melting Curves by McGhee's Algorithm; 4.2.4 Case Studies: Bisintercalating Anthracyclines and Echinomycin; 4.2.5 Summary: Advantages and Pitfalls; 4.3 High-throughput Thermal Denaturation Approaches; 4.3.1 Differential Scanning Fluorimetry; 4.3.2 DSC Compared with DSF: Slow and Expensive but Definitive; 4.3.3 Illustrations of Differential Scanning Fluorimetry Data and Utility; 4.3.4 Advantages and Prospects; 4.4 Summary; Acknowledgements; References
Text of Note
Chapter 5 Computer Simulations of Drug-DNA Interactions: A Personal Journey5.1 Introduction; 5.2 Minor Groove DNA Binders; 5.3 Natural Bifunctional Intercalators and Hoogsteen Base Pairing; 5.4 Bis-intercalation of Echinomycin and Related Bifunctional Agents in Relation to Binding Sequence Preferences; 5.5 Binding Preferences of Synthetic Pyridocarbazole Bis-intercalators; 5.6 Sequence Selectivity of Actinomycin D; 5.7 Binding of the Potent Antitumor Agent Trabectedin to DNA; 5.8 Other Examples of DNA Minor-groove-bonding Tetrahydroisoquinoline Antibiotics; 5.9 Melting DNA on the Computer
0
8
8
8
SUMMARY OR ABSTRACT
Text of Note
This book explains key aspects of the progress that has been made towards understanding how drugs can bind specifically to nucleic acids, and thus underpin the endeavour to make gene targeting a reality. The binding of drugs to DNA is a fast developing area of research with important applications in medicine, particularly the treatment of cancer. Early chapters cover methodologies to evaluate DNA-interactive agents and then the book provides examples of DNA-interactive molecules and technologies in development as therapeutic agents and treats in depth topics such as DNA-binding metal complexes, peptide and polyamide-DNA interactions.